In the CAR2BRAIN phase I trial administering HER2-specific CAR NK cells, in the escalation cohort, cells are first administered intracranially into the wall of the resection cavity during relapse surgery (in patients with a planned partial or total resection) or into the tumor (in patients with a planned biopsy). Here, ERBB2 is linked to neoplasm.